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ABSTRACT
Dietary Sodiiim and the Premenstrual Syndrome
September 1983
Judith Nissenbaiim, B.A., Brandeis University
M.S., Ph.D., University of Massachusetts
Directed by: Professor Bonnie R. Strickland
The present study was a double-blind placebo-
controlled investigation of the effect of reduced dietary
salt on premenstrual syndrome. Dependent measures
included subjects' self-reports of moods and water
retention during four phases each of six monthly cycles.
Subjects' weight and blood pressure were measured three
times during each cycle. After two baseline cycles, all
subjects started a reduced sodium diet. In addition, half
the subjects took 4 grams of salt per day in capsule form,
thereby approximately replacing the salt they removed from
their diet (placebo condition). The rest of the subjects
took identical capsules containing an inert substance
(reduced salt treatment condition). After two months the
cross over took place: subjects in the placebo condition
began the treatment condition by having their salt cap-
sules replaced by inert capsules, and vice versa. Thus
all subjects underwent two cycles each of baseline,
placebo, and treatment.
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During baseline subjective water retention was the
only consistent premenstrual change observed. Self-report
mood symptoms and physiological symptoms either did not
show the expected menstrual cycle pattern or were not
consistent over the two months. Treatment effects were
therefore inconclusive, especially in view of the small
number of subjects completing the study. No significant
premenstrual differences between baseline, placebo, or
treatment conditions were observed. When measures were
averaged across each cycle, however, MAACL anxiety was
significantly lower during treatment than during baseline.
Excluding an extreme weight loss subject from analyses,
weight during treatment was significantly lower than
baseline, and a decrease in systolic blood pressure during
treatment approached significance.
Extreme variability in baseline measures raises
questions of methodology for this type of research. A
longer time for both baseline and treatment conditions may
be required before valid premenstrual data will emerge.
Other factors, such as environmental stress and dietary
factors, must be taken into account in studying the
premenstrual syndrome. The fact that reduced dietary
sodium had an effect on overall anxiety level and on blood
pressure in a normotensive population may have
vii
important implications for preventive aspects of research
on hypertension.
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CHAPTER I
INTRODUCTION
Fluctuations in physical and psychological states have
long been associated with women's monthly hormonal cycling.
While the effects of menstrual cycle changes have for ages
variously influenced women in their lives and legends, not
until this century has scientific documentation of those
phenomena begun to accumulate. Recent reviews have cited
evidence for increased incidence of numerous problems for
women during the premenstruum. While these seem to be
quite minor for most women, some of the more pronounced
negative reactions include depression, anxiety, suicidal
behavior, psychiatric hospital admissions, epileptic
seizures, allergic reactions, accidents, and criminal
behavior (Smith, 1975; Reid and Yen, 1981). Although
for many women premenstrual symptoms do not require
professional interventions, epidemiological evidence
suggests that from 70% to 90% of all women report
recurrent premenstrual symptoms, and 20% to 40% of women
experience some degree of temporary mental or physical
dysfunction premenstrually (Reid and Yen, 1981).
Current popular women's literature abounds with
polemical discussions of premenstrual syndrome. On the
one hand, it is argued that, contrary to tradition, women
1
do not become less functional or capable as a result of
monthly cycling, and that they should therefore not be
treated differently on account of the phase^s of their
cycles. (Research shows, in fact, that premenstrual or
menstrual symptoms do not generally interfere with actual
task or job performance [Sommer, 1973]). On the other
hand, some have argued that menstrual cycle effects are a
biological reality and must be taken seriously and not be
patronized or dismissed. This view is exemplified in its
extreme by recent highly publicized court cases where
premenstrual syndrome has been used in the defense of
women who have committed violent acts.
Political controversy aside, it can be asserted that
menstrual cycle changes do have both biological and psycho
social reality for women. Serious and rigorous research
in the area must continue for the purpose of clarifying
the nature of those realities. Research is also essential
in order to help make available the informed choices
necessary for women to be able to maximize their own
potential for physical and mental well-being. For example
some traditional treatments, such as progesterone
injections, are being shown in controlled research either
to be ineffectual, or to be effective for only a small sub
group of women who experience menstrual cycle symptoms.
More refined and well-controlled research can identify
specific sub-groups of women who might respond to
3particular treatments, and also can test and develop
alternative, less invasive treatments, such as changes in
activity levels and diet. Investigating the effects of
dietary sodium changes is an important step in this
direction, since sodium and fluid retention are common
premenstrual complaints.
Description of the Premenstrual Syndrome
The descriptive terminology used with reference to
menstrual cycle symptoms is often unclear and imprecise.
"Dysmenorrhea" may or may not refer to "premenstrual
syndrome," which may or may not include "premenstrual
tension." This confusion may be partly because
premenstrual and menstrual symptoms are in fact not always
clearly separable. While there may be some overlap of
symptoms between the premenstrual and menstrual phases of
the cycle, however, recent research strongly suggests that
those two cycle phases are generally characterized by two
different types of symptoms. The two syndromes are not
mutually exclusive as some previous investigators have
suggested (Chesney and Tasto, 1975); that is, women can
experience either, neither, or both menstrual and
premenstrual symptoms
.
The symptoms most usually associated with the
menstrual phase of the cycle include cramps or spasms of
pain, nausea, and dull, continuous pain. Premenstrual
symptoms tend to be more variable both in their nature and
the time of their occurrence, which may be any time from
ten days to two weeks prior to menstruation to just a day
or two before the onset of menstruation. Physical symptoms
may include headache, backache, fatigue, and skin problems.
Among the most common physical symptoms are swelling and
tenderness of breast or abdominal tissues, bloating, and
changes in appetite and food intake—notably cravings and
increased consumption of sweet and salty foods. Psychol-
ogical symptoms can include depression, irritability,
anxiety, poor concentration, sadness, emotional lability,
and lethargy (Reid and Yen, 1981; Smith, 1975). Different
women may experience various combinations of symptoms at
different levels of severity. Even the same women may
sometimes experience different levels and types of symptoms
from one cycle to another. Moos (1977) has factor analyzed
data obtained from more than 800 women, and has identified
six major symptom clusters which seemed to differentiate
the premenstrual phase from the intermenstrual phase. He
labeled these clusters pain, concentration, behavior change,
autonomic reactions, water retention, and negative affect.
In addition. Moos and Liederman (1977) computed cluster
analyses of data gathered from more than 500 subjects and
identified a variety of symptom patterns. Yet, as Moos
and others have pointed out (e.g., Clare, 1979; Smith,
1975), much of the menstrual cycle research that has been
done has assumed a single premenstrual syndrome. The
results of this large body of research, even from the
small percentage of studies that have been well controlled,
are contradictory and inconclusive. Attempts to identify
a single cause or a universally effective treatment have
not succeeded simply because it is likely that there are a
variety of possible causes and therefore a variety of
potentially effective treatments for different premenstrual
syndromes
.
Etiologies of PMS
Early theories, and even some more recent opinion,
have often attributed premenstrual symptoms to women's
negative attitudes toward menstruation, sex, or sex roles.
Socio-cultural attitudes were said to affect women's
expectations about premenstrual symptoms such that these
expectations actually led to women's experiencing of
premenstrual symptomatology. Negative attitudes toward
menstruation as acquired by some kinds of religious
training or other sources of early attitude development
have been seen to be related to severity of menstrual
cycle symptoms. According to this view, women learn that
they are expected to be ashamed, embarrassed, and dysfunc-
tional at certain times during their cycle, and they
interpret their own experiences and feelings in concordance
with those socio-cultural expectations.
6Since many of the symptoms of premenstrual syndrome
involve subjective psychological phenomena such as mood
states, problems of measurement become particularly
relevant to these kinds of studies. Responses to self-
report symptom checklists can be as much a product of
subjects' expectations as of their hormone balance. For
this reason, it is especially important that premenstrual
syndrome studies involve blind, placebo controlled research
designs. Placebo effects tend to abate over time, while
treatment effects are not as likely to lessen.
Environmental stresses also play an essential role in
premenstrual syndrome, since one of its characteristics
may be that a woman's vulnerability to stress is more
acute premenstrual ly than at other times during her cycle.
This factor is an important contributor to high intra- and
intersubject variability of reported symptomatology. In
addition, some investigators, notably those with a
psychoanalytic orientation, have attempted to associate
certain personality types or individual neurotic tendencies
with menstrual cycle problems (e.g., Coppen and Kessel,
1963; Rees, 1953). While it is not likely that such
factors account for all menstrual cycle symptomatology,
it stands to reason that they would affect women's
perceptions and reports of their symptoms . Most recent
thinkers in the area of menstrual cycle research acknow-
ledge that biological, social, and psychological factors
are interacting contributors to women's experiences of pre-
menstrual symptoms (Ruble, Brooks-Gunn, and Clark, 1980).
The importance of social and psychological factors
notwithstanding, the majority of premenstrual syndrome
studies have attempted to isolate biological factors as
causes of the problems. Fluctuating levels of estrogen
and progesterone through the menstrual cycle have until
recently been the primary focus for researchers investi-
gating its biological aspects. Frank (1931) was the
earliest worker to suggest that excessive estrogen caused
premenstrual symptoms. Israel (1941) elaborated by
proposing that it was excessive estrogen in relation to
progesterone, or unopposed estrogen, which caused symptoms.
Subsequently a number of authors have reported evidence
supporting the unopposed estrogen theory (Morton, 1950;
Widholm, Frisk, Tenhunen, and Hartling, 1967; Cullberg,
1972; Backstrom and Mattsson, 1975). Others, however, have
questioned these findings. Munday (1977), for example,
reported that premenstrual symptoms often preceded the
shift in the estrogen/progesterone ratio, and that in any
case only 30% of patients with severe symptoms showed the
low progesterone concentrations. O'Brien, Selby, and
Symonds (1980) demonstrated that changes in progesterone
levels did not coincide with the appearance of significant
premenstrual symptoms
.
A number of reports have presented evidence that pre-
8menstrual syndrome is a progresterone withdrawal phenomenon
(e.g., Greene and Dalton, 1953) or an allergic response to
endogenous hormones (Zondek and Bromberg, 1945). Although
these reports have not been substantiated, research findings
in the area of endocrine allergies continue to accumulate
(Mabray, 1983).
Other homones besides estrogen and progesterone have
been implicated in premenstrual syndrome. In particular,
recent evidence about the possible regulatory role of
prolactin is of interest. Carroll and Steiner (1978)
have suggested that excessive prolactin may interact with
estrogen and progesterone levels to produce various mood
symptoms, and with renal hormones to affect fluid and
sodium retention. Andersch, Hahn, and Isaksson (1978)
and Halbreich, Ben-David, Assail, and Borstein (1976) have
published similar reports. Some evidence has been noted
wherein large doses of vitamin B^ have reduced prolactin
levels and alleviated premenstrual symptoms (Delitala,
Masala, Alagna, and Devilla, 1976). Contradictory evidence
with regard to the role of prolactin in the premenstrual
syndrome have been reviewed in O'Brien, Selby, and Symonds
(1980) and in Reid and Yen (1981).
Vitamin B^ has also been implicated in premenstrual
syndrome by other theorists. Rose (1978) has suggested
that excessive estrogen leads to a vitamin B^ deficiency.
Since vitamin B^ is important in the synthesis of dopamine
and serotonin, a diminution of these substances could
result when estrogen levels are excessive. The role of
\
vitamins, especially the B vitamins, in the synthesis of
these and other neurotransmitters is complex, and not yet
clearly understood. There is growing evidence that cate-
cholamines play a role in regulating the hormones vasopres-
sin, renin, and angiotensin that interact to control sodium
and fluid balance. Research in this area continues to
associate additional brain, pituitary, and renal substances
in the cycling of sodium and fluid regulating processes as
well as in other menstrual cycle manifestations. Reid and
Yen (1981) have summarized the possible interactions of
dopamine, beta-endorphins and other neuropeptides, and
prostaglandins—all biochemical substances that may
contribute to menstrual cycle symptomatology.
Other metabolic processes may be implicated in men-
strual cycle problems
. Some investigators have suggested
that cyclic changes in glucose tolerance may lead to
premenstrual symptoms (e.g., DePirro, Fusco, Bertoli,
Greco, and Lauro, 1978). Reid and Yen (1981), however,
have reviewed evidence suggesting that while cyclic shifts
in glucose metabolism may account for some cyclic appetite
changes, they are not related to other premenstrual
symptoms. Moreover, appetite changes seem to be too wide-
spread a premenstrual phenomenon to be explained by what
is probably only a small percentage of individuals with
10
abnormal glucose tolerance levels. in addition, there is
evidence that cyclic changes in sodium appetite are at
least as significant as other appetite changes (Weizenbaum,
Benson, Solomon, and Brehony, 1979; Dillon, 1983). Very
little research has been done in the area of sodium
appetite, in spite of the well-established phenomenon of
premenstrual water and sodium retention.
Although its relationship to sodium appetite has not
been investigated, fluid retention itself has been a major
focus of attention in studies of the premenstrual syndrome.
Fluid build-up premenstrually has been assumed to be
related to increased premenstrual sodium retention, but
the underlying mechanism for these changes is not clear.
Some investigators have reported that premenstrual fluid
retention is not in itself a clear-cut phenomenon. Taggart
(1962) and Michelakis, Stant, and Brill (1971) have
published evidence that women do not typically show
premenstrual weight gain. Others have reported average
weight gain of one to three pounds premenstrually (Watson
and Robinson, 1965). Preece, Richards, Owen, and Hughes
(1975) have noted that localized premenstrual swelling
(e.g., of the breast tissues) can occur even though there
may be no overall weight gain. Still other investigators
(e.g., Janowsky and Berens, 1973) have noted a correlation
between premenstrual weight gain and severity of
premenstrual negative mood symptoms. Others have failed
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to show such a relationship (Golub, Menduke. and Conley,
1965).
Fluid and electrolyte balance are regulated by the
renin-angiotensin-aldosterone system. Both estrogen
(Preedy and Aitkin, 1956) and progesterone (Oelkers,
Schoneshofer, and Blumel, 1974) have been implicated
in increasing levels of plasma renin substrate and
aldosterone, leading to sodium and fluid retention. Reid
and Yen (1981) have pointed out that, while accumulated
research evidence suggests that sodium and fluid retention
as well as other aspects of premenstrual syndrome are
related to a dysfunction along the hypothalamic-pituitary-
ovarian axis, the actual mechanisms of the dysfunction or
dysfunctions remain elusive.
Treatments for PMS
Even though a clear understanding of the causes of
premenstrual syndrome has not yet been achieved, many
treatments have been developed, with varying degrees of
reported success. A number of psychotherapeutic approaches
have been brought to bear on the problem, ranging from
psychoanalysis to relaxation and desensitization
therapies. Reports of their success have been largely
anecdotal (see the review in Tasto and Insel, 1977),
but Chesney and Tasto (1975) showed in a controlled study
that a muscular relaxation training program was effective
12
in alleviating menstrual (or what the authors called
spasmodic) discomfort but not premenstrual (congestive)
symptoms. A variety of psychoactive drugs have also been
tried as treatments for premenstrual syndrome. Pennington
(1957) reported 78 percent success with Meprobamate
(Miltown). Lithium was reported to relieve a number of
premenstrual symptoms in eight women in an uncontrolled
study (Sletton and Gershon, 1966). A later investigation
tested lithium in a double-blind placebo controlled study
and found no differences between placebo and lithium
(Singer, Chang, and Shore, 1974). It could well be that
psychotherapy or the use of psychoactive medications may
have benefits for some women suffering from premenstrual
symptoms. Indeed, psychological interventions often
provide useful adjunctive treatment for individuals who
experience any of a variety of chronic physical problems.
Given the widespread interest in the role of
progesterone/estrogen balance in premenstrual syndrome, it
is not surprising that oral contraceptives have been used
in its treatment. Smith (1975) has reviewed the literature
on this topic, which has showed mixed results. Culberg
(1972) and Moos (1969) in studies of large numbers of users
and non-users of oral contraceptives concluded that fewer
premenstrual symptoms were experienced by women using
various types of oral contraceptive pills. Given the
powerful effects of oral contraceptives on natural hormone
13
balance and function, as well as potential discomfort and
danger from side effects of this treatment, it is question-
able whether larger numbers of women would or should elect
to use oral contraceptives solely for the purpose of
alleviating premenstrual syndrome.
The same caveat should apply to the use of progester-
one and to synthetic progesterones
, which have been even
more popular as treatments for premenstrual syndrome.
Dalton (1964, 1977) has perhaps been the most active pro-
ponent of the use of progesterone as the treatment of
choice for premenstrual syndrome. Yet she has only
published evidence from uncontrolled clinical trials of
progesterone. Sampson (1979) has reported a double-blind
placebo controlled trial of progesterone in which proges-
terone did not differ from placebo in its effectiveness.
Investigators studying the role of prolactin in
mediating estrogen/progesterone balance in premenstrual
syndrome have claimed that bromocriptine, known to reduce
prolactin levels, is an effective treatment for
premenstrual syndrome (Carroll and Steiner, 1978). Other
researchers, however, show negative results for the same
treatment, using controlled studies (Ghose and Coppen,
1977; Graham, Harding, Wise, and Barriman, 1978).
Following the discoveries of the roles of some vitamins
in the synthesis and metabolism of various neurotransmitters
and hormones, vitamin treatments of premenstrual syndrome
14
gained considerable popularity, but no well controlled
studies have been done to adequately test their efficacy.
Some evidence from a controlled study exists suggesting
that vitamin is an effective treatment for depression
occurring as a side effect of some oral contraceptives
(Adams, Rose, Folkard, Wynn, Seed, and Strong, 1973).
Stokes and Mendels (1972), however, looking directly at
the effect of vitamin on premenstrual syndrome, found
generally negative, though mixed, results. Other vitamins,
especially A, and some minerals have been reported to be
effective, but these reports have not been from controlled
studies. Reid and Yen (1981) have reviewed the vitamin
treatment literature.
Recent interest in the role of prostaglandins in the
menstrual cycle have given rise to the development of new
treatments. Some investigators hold that an excess of
prostaglandins cause premenstrual symptoms. In a double-
blind study. Wood and Jakubowicz (1980) found that
mefenamic acid (an antiprostaglandin) was highly effective
in alleviating a number of premenstrual symptoms, especi-
ally negative mood symptoms. On the other hand, some
theorists have claimed that premenstrual syndrome is
related to prostaglandin deficiency, which can be treated
with gammalinoleic acid (Hoes, 1980). While this substance
(found in oil of evening primrose) has been reported
effective in clinical trials, no controlled studies have
15
been published to date.
Fluid retention, along with its various manifestations,
has been seen as one of the target symptom groups fo^ many
treatments, even though its relationship to other
premenstrual symptoms has remained unclear. Treatments of
premenstrual fluid retention have focused on the use of
diuretics. As with other treatments, much of the research
reported using diuretics has been uncontrolled or poorly
controlled. Some investigators have reported diuretics
to be effective in relieving specific symptoms. Greene
and Dalton (1953) and Thomas (1933), for example, reported
that premenstrual headaches were relieved by diuretics
.
Reid and Yen (1981) have reviewed and critiqued a number
of poorly controlled studies using diuretics. Mattsson
and Schoultz (1974) and Andersch, Hahn, and Isaacson (1978)
found that both diuretics and placebo were effective in
double-blind studies. These studies failed to encompass
a time period sufficient for placebo effects to abate so
that possible lasting effects of the treatment could be
observed. In another controlled study (Jordheim, 1972),
diuretics were used in conjunction with other substances,
making it impossible to draw conclusions about the effects
of specific substances.
Indeed, diuretics may not be an appropriate treatment
for premenstrual fluid retention. Like other chemical
interventions, diuretics may pose a risk of unwanted side
16
effects. Huapaya and Ananth (1980) have suggested that
one side effect of diuretics may be depression—one of
the major symptoms associated with premenstrual syndrome.
Another reason diuretics have failed to provide consistent
relief for premenstrual symptoms may be that these
medications have a superficial and short-term effect of
relieving some fluid retention, without altering a more
fundamental electrolyte imbalance that could be related to
the excessive dietary salt intake which is pervasive in
this culture (Dillon, 1976; Tuthill and Calabrese, 1981b).
The need for salt in human beings has been shown to be
between one and two grams per day, yet the daily median
salt intake for individuals in this country ranges between
three and ten times that amount (Tuthill and Calabrese,
1981b). Furthermore, Dalvit (1981) has reported strong
evidence that females significantly increase their total
food intake premenstrual ly. She followed eight females
trained in nutritional record-keeping for two menstrual
cycles in a double-blind study. She found that for all
sixteen cycles the mean caloric intake for ten postovula-
tion days (premenstrual) was on average 500 calories
greater than the mean intake for ten preovulatory days.
In this study, subjects also recorded their weight, which
showed no significant fluctuations associated with
menstrual cycle phase. Although Dalvit did not investigate
changes in specific foods consumed, Weizenbaum, Benson,
17
Solomon, and Brehony (1979) have shown that for at least
some women there is a tendency to increase intake of sweet
foods and especially of salty foods premenstrually. If
this is the case, the already high level of dietary sodium
may be even higher for some women during the premenstrual
phase of their cycles. No research on the connection
between dietary sodium intake and premenstrual syndrome
has been reported to date.
Statement of the Problem and Hypotheses
The present study will attempt to answer a number of
questions. Does the level of dietary sodium intake
increase premenstrually? If the overall dietary sodium
level is reduced, how are specific premenstrual symptoms
affected; especially weight gain, subjective experience of
fluid retention, anxious mood, and depressed mood? Is
there a placebo effect on premenstrual symptoms if women
believe they are reducing their salt intake and receiving
dietary supplements?
In order to address these questions the present study
will assess changes in dietary sodium intake over a
two-cycle baseline period. Other menstrual cycle changes
will be assessed as well, with a focus on the specific
premenstrual levels of fluid retention, depression, and
anxiety. Dietary levels of sodium will then be altered,
and changes in symptom patterns assessed.
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The following hypotheses will be tested:
1. Subjects will show less premenstrual fluid
retention, as measured both subjectively and objectively
when their overall dietary sodium intake is reduced.
2. Subjects will show lower levels of premenstrual
depression when their overall dietary sodium intake is
reduced.
3. Subjects will show lower levels of premenstrual
anxiety when their overall dietary sodium is reduced.
CHAPTER II
METHOD
Design
A placebo controlled double
-blind crossover procedure
was used in this study to test the effect of a moderate
low sodium diet on specific aspects of premenstrual
disturbances. All subjects kept regular records of
physical symptoms, moods, diet, activity, and stress levels
for a total of six monthly cycles. Three times per month
subjects brought their records to the experimenter's
laboratory office and had their weight and blood pressure
checked. For the first two cycles (baseline period)
subjects made no dietary change. At the beginning of the
third cycle all subjects were given detailed instructions
for going on a moderate low sodium diet; i.e., they were
given lists of specific foods to avoid or cut down on (see
Appendix A). At the same time half the subjects were
given a supply of one-half-gram capsules of salt, with
instructions to take eight per day (placebo phase). It was
estimated that this amount of salt per day (four grams)
would approximately replace the amount of salt eliminated
by the dietary change, thereby making this group the "no
dietary change" group, but at the same time keeping them
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(and the research assistants working with them) blind to
their condition. The other half of the subjects were given
capsules identical in taste and appearance to the salt
capsules, but containing one-half
-gram of dextrose instead
of salt (treatment phase). These subjects were also
instructed to take eight capsules per day; this group was
the experimental group actually on the low sodium diet.
After two complete cycles (cycles three and four) came the
crossover phase: subjects who had completed the two month
placebo phase were given inert capsules for their treatment
phase (cycles five and six), and subjects who had completed
their treatment phase were given salt capsules for their
final two-month placebo phase (see Tuthill and Calabrese,
1981a, from whom this method of altering dietary sodium
intake was adapted). Subjects' self-reported premenstrual
symptoms for baseline, placebo and treatment phases were
tested for differences and for any order effect. In
addition, office measures of weight and blood pressure were
tested for changes between experimental phases.
Researchers
Two female graduate students in Clinical Psychology
were in charge of the overall administration of the study.
One of these two graduate students trained and supervised
the five female undergraduate psychology majors who
functioned as research assistants. The research
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assistants conducted the initial and ongoing interviews
with subjects, collated and coded data, and prepared and
distributed individualized feedback for subjects after
the study was finished.
The other graduate student researcher, the author
of this dissertation, also worked with the research
assistants, and was in charge of coding, scheduling, and
distributing the capsules according to the crossover
design. Researchers who met with subjects were aware of
the nature and purpose of the study, but after the baseline
period they were blind to the condition of the subjects at
any given time.
All researchers and research assistants were female,
since it was expected that subjects might feel more
comfortable discussing their menstrual cycles with females
rather than with males.
Subject Selection
Telephone screening . A number of criteria were used to
screen subjects for participation in this study. An
advertisement was placed in local newspapers and posted in
a variety of public places requesting volunteers:
TROUBLED BY
PREMENSTRUAL TENSION/DEPRESSION?
Volunteers needed for a study of
premenstrual distress being conducted
at the University of Massachusetts,
Amherst, in the Psychology department.
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Women who experience psychological
and/or physical discomfort prior to
their menstrual periods are invited to
participate.
\
Volunteers must be willing to keep
regular records, and report in regularly
for up to seven months.
[A phone number was listed here
for interested subjects to call to
obtain further information.]
When interested women called in to enquire about the
study, trained research assistants gave the following brief
description of the study:
We are looking at the effects of
certain dietary changes on premenstrual
symptoms. We'll be asking you to keep
records at home, which consist of
filling out a number of daily check-
lists for several days during each
menstrual cycle. In addition, we'll
be asking you to come into our office
three times each month to have your
weight and blood pressure taken, and to
bring us your completed checklists and
pick up new checklists. This home
record-keeping and office visit routine
will proceed for the entire duration
of the study, which will be six monthly
cycles. For the first two monthly
cycles, we won't ask you to make any
dietary changes; this is our baseline
period, which will be a time for you
to get used to the record-keeping
procedures. At the end of the first
two cycles we'll be asking you to cut
down on the amount of salt in your diet.
This will mean that you won't be adding
salt to your food, also that you'll be
eliminating or cutting down on certain
foods that contain a lot of salt. We'll
give you detailed instructions for this
moderately low-salt diet when the time
comes. At the same time you start this
dietary change, we'll be giving you some
capsules to take every day. Although we
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can;t tell you what the capsules contain
until you have completed the study, we
can assure you that they contain nothing
that IS a drug or that could be harmful.
They will contain either a normal
quantity of a dietary supplement, such
as a vitamin or mineral, that you could
readily purchase, or they might contain
a placebo or inert substance. Again,
we'll inform you about what you have
taken after the study is finished.
After you have completed the
entire six-month study, we'll pay you
$80, in appreciation for your partici-
pation. If you do not complete the
entire study, but if you do complete
at least four of the six cycles, we'll
pay you $25.
During this explanation, the telephone interviewer
periodically stopped to ask whether the subject was
understanding, and to clarify if there were any questions.
If the potential subject continued to be interested after
hearing this description, the research assistant asked her
to respond to a few qualifying questions before scheduling
an initial face-to-face interview. Subjects were not
accepted for the study if they 1) were taking, had recently
been taking or were planning to take (before the end of the
study) oral contraceptives or other hormonal medications;
2) had high blood pressure, kidney disease, or any other
disorder that could be affected by change in dietary
sodium, 3) were unable to control their own diet (e.g.,
if they were on a meal plan in a dormitory). In addition,
it was explained to subjects that as they would be asked
to participate for six monthly cycles, they should not
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volunteer if they were planning to move (or become
pregnant) within the next half year. Subjects were asked
to rule themselves out if they did not have "more-or-less"
regular cycles, although it turned out that cycles were
extremely variable and unpredictable for many subjects.
It was initially planned that subjects would be
screened according to specific premenstrual mood symptoms—
specifically, depression or anxiety—so that they could be
divided into two groups. Because of the small number of
subjects, however, and because of a large proportion of
subjects reporting both premenstrual anxiety and depression,
this plan was not found to be feasible. In addition, an
initial age restriction, intending to include only women
over 25, was dropped because of insufficient numbers of
subjects volunteering.
Women who qualified according to the criteria
described above were scheduled for an initial screening
interview with one of the research assistants, where they
were to be given a number of questionnaires to fill out
and where the details of their participation were to be
explained.
Initial interview . The initial interview took from one
to one and a half hours. Each subject met with the
research assistant to whom she had been assigned in a
comfortable, softly lit office. The interviewer chatted
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informally with the subject for a few moments to put her
at ease, and then described in detail—reiterating and
elaborating the information already given on the
telephone—what the subject would be required to do to
participate in the study. if the subject agreed, she was
asked to sign a consent form (see Appendix B).
The research assistant first mapped out the subject's
schedule of record keeping and office visits according to
her menstrual cycle. This was done with a chart and a
sample of a 28-day menstrual cycle (see Appendix C). The
research assistant asked the subject to recall the date
her last menstrual flow began and to report the average
length of her cycle. From this information, the probable
starting date of the next cycle was estimated (in this
study, as has been customary in menstrual cycle research,
the first day of menstruation is designated as day one in
a given cycle). The date of ovulation was estimated by
figuring ahead to the beginning of the second cycle (after
beginning the study) and then moving back exactly 14 days.
For example, if a subject with a 31-day cycle expected her
period on November 10, the following cycle would begin on
December 11. Fourteen days before that is November 27,
the day when ovulation would be most likely to occur.
With this projected timetable, a total of twelve
packets of daily record-keeping questionnaires were
scheduled for the first upcoming menstrual cycle. The
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first three packets were to be filled out at the end of
each of the first three full days of the cycle. The
second group of questionnaire packets were to be filled
out at the end of each of a block of three days during
the follicular phase (that part of the cycle after
menstruation up until ovulation). An office visit was
scheduled after this second set of packets, also prior
to ovulation. The third set of packets was scheduled to
be filled out during the luteal phase—sometime during the
week after ovulation. An office visit was scheduled
immediately after these packets, also during the post-
ovulation week. The fourth and final set of packets was
scheduled to be filled out for three days during the last
week of the cycle—the premenstrual phase. The third
office visit was scheduled for the day after these packets
were to be completed, ideally just one or two days before
the next cycle was to begin. (The sample 28-day menstrual
cycle. Appendix C, shows how the record-keeping and office
visits were to be planned.
)
When the subject clearly understood her individual
schedule, a tentative appointment for the first office
visit was made. It was understood that if the subject's
cycle started on a different day than expected, the
schedule would have to be revised accordingly. Research
assistants exchanged phone numbers and available times
with their subjects so that reminders and changes in
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schedule could be easily communicated.
After the scheduling was completed, the subject had
her weight and blood pressure recorded. Weight and blood
pressure were taken at the initial interview primarily to
familiarize subjects with these procedures, which would be
part of the office visit routine. The blood pressure check
also afforded direct evidence that subjects did not have
high blood pressure. All subjects did in fact show blood
pressure levels within normal range. Since subjects did
not all undergo the initial interview at the same point
during their menstrual cycle, these weight and blood
pressure measures were not used for correlational purposes.
Following the weight and blood pressure checks, the
subject was given a packet of questionnaires to fill in
(Appendices D and F), with the research assistant giving
instructions for completing the forms. These question-
naires were given in order to gather some demographic data,
as well as some retrospective reports about subjects'
menstrual cycle experiences. A number of these initial
questionnaires were similar to the questionnaires in the
daily packets. These similarities, along with differences
in instructions, were explained carefully to the subject.
When the subject had completed all the initial ques-
tionnaires, she was given six daily questionnaire packets
(for the first two sets of three days of her next cycle)
and a copy of her menstrual schedule. The interviewer
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went through the home record-keeping packet with the
subject, giving detailed instructions for completing the
packets. The material contained in these packets was
similar to some of the initial interview material just
filled out by the subject, so that this material was used
as a reference point for the explanation of the home
record-keeping packets. After making sure any questions
the subject had were answered, the research assistant
ended the interview with a promise to call the subject
with a reminder to begin the daily record-keeping when her
next cycle was to begin.
Office Visits
Three times during each of the menstrual cycles for
the duration of their participation in the study, subjects
reported to the office for a brief visit. During each of
these visits, the research assistant collected weight and
blood pressure, using the same doctor's office scale and
blood pressure kit each time. In addition to providing
the opportunity to collect the home record data and the
physiological data, the office visits provided the oppor-
tunity for personal contact between the subject and the
research assistant. It was expected that this contact
would provide motivation for the subjects to follow through
with their participation in this lengthy project.
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Final Follow-Up Visit
Following the subject's final office visit of their
last cycle, a follow-up visit was scheduled. During this
visit the subject was debriefed and given detailed feedback
as to the nature of the study as well as which cycles she
was in the treatment and placebo conditions. Subjects were
given checks at this time for the amount of money promised
them as payment for their participation.
The Initial Interview Questionnaires
Self-report cpiestionnaire
. Some demographic data were
collected from subjects in order to look at possible
correlations with patterns of premenstrual symptoms
(Appendix D). In addition, it was considered important to
have this information so that differences between subjects
who completed the study and those who dropped out could be
examined. Information regarding subjects' age, occupation,
marital status, education, income level, and number of
children was recorded.
Subjects were asked to rate their "usual" activity
level and appetite, on a one to seven scale. These same
ratings for specific days were included on the daily record
forms. Subjects' self-reports of their "usual" activity
and appetite levels would then be compared with changes in
these measures over the menstrual cycle.
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Subjects' estimates of their daily caffeine intake,
as well as their reports of regular medications (dosage
and frequency) were also collected during the initial
interview. Finally, subjects were asked to report any
notable occurrences or events (positive or negative) within
the last month which might have a stressful or disruptive
effect on them.
MAACL. The Multiple Affect Adjective Check List (Zuckerman
and Lubin, 1965), a 132-item check list, yields three
affect scale scores: depression, hostility, and anxiety.
Normative data, as well as the discriminant validity and
high reliability of this instrument have been reported by
Zuckerman, Lubin, and Robins (1965) and Pankratz, Glaudin,
and Goodmonson (1972). Subjects were asked to check those
items that described their overall mood state for the past
month
.
Menstrual Distress Questionnaire, Form A (retrospective) .
The Moos Menstrual Distress Questionnaire (Moos, 1977)
lists 47 symptoms to be rated on a six-point severity
scale (Appendix F). The retrospective (Form A) version of
this instrument requires subjects to rate each symptom
three times : for the time during the most recent
menstrual flow, the time during the week preceding the most
recent flow, and for the remaining time of the most recent
menstrual cycle. The eight symptom clusters identified
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by Moos' (1968) factor analyzed data from 839 subjects
are pain, concentration, behavior change, autonomic
reactions, water retention, negative affect, arousal, and
a control scale which included symptoms not usually
specified by women premenstrually
. Extensive data on the
validity, reliability, and stability of the Menstrual
Distress Questionnaire have been reported and reviewed by
Moos (1977).
Food frequency list
. The food frequency list was devised
to assess roughly the amount of sodium in subjects' daily
food intake (Appendix G). The list included a wide variety
of foods with moderate to high sodium content, as well as a
number of filler items so that subjects would not be con-
scious that the check list was primarily designed to evalu-
ate sodium intake. Subjects were required to give an
estimate of how many servings of each item they had con-
sumed during the last month. The lists were scored simply
by totaling the number of servings of keyed sodium items.
Health history questionnaire . The final instrument filled
out by subjects at the initial interview was a health
history questionnaire (Appendix H). Since the data from
this questionnaire were not used for this study, it will
not be described here.
32
The Home Record-keepincf Questionnaires
Self-report questionnaires. The face sheet of each daily
packet required the subject to record ratings of her
appetite and activity level for that day, on seven-point
scales (Appendix I). Subjects were also asked to report
any medications taken that day, including prescription,
non-prescription, and recreational substances taken.
Caffeine consumption was to be reported. The final ques-
tion on this questionnaire requested the subject to report
any food cravings she had experienced that day, and whether
or not she had eaten the foods she craved.
MAACL, short form
. The short form of the Multiple Affect
Adjective Check List, like the long form, yields three
scale scores: depression, anxiety, and hostility, but
contains only 63 items (Appendix J). Its validity and
reliability, as well as its statistical relationship to the
long form, have been reported by Zuckerman, Lubin, and
Robins (1965). Subjects were asked to check the items that
described their mood for the particular day they were
recording.
Menstrual Distress Questionnaire, Form T . Form T of the
Moos Menstrual Distress Questionnaire lists the same 47
symptoms contained in Form A, with the same six-point
severity scale for each symptom. On Form T, however, each
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symptom is rated only once, for the specific day the
subject was recording. Moos (1977) has reported and
reviewed data regarding th^ validity, reliability, and
stability of this instrument.
Food frequency list. The food frequency list was identical
to the one subjects had filled out during the initial
interview. The instructions, however, directed subjects
to report only foods they had eaten during that single day.
Physiological Measures
Weight
. Subjects were weighed with clothing but without
their shoes, using a doctor's scale.
Blood pressure
. Blood pressure was measured with subjects
in a sitting position, using a standard cuff sphygmamometer
.
CHAPTER III
RESULTS
Sununary
Of 46 subjects who took part in the initial interview
screening 33 continued at least long enough to contribute
baseline data, and ten completed the entire six-month
sodium reduction study. No differences on demographic or
initial interview variables were found among these groups.
While the retrospective questionnaire showed expected
increases in premenstrual negative moods and subjectively
experienced water retention, daily records kept during the
two month baseline period showed a consistent premenstrual
increase only in experienced water retention, but not in
negative mood symptoms
.
Given the fact that baseline data did not show
expected premenstrual patterns, and considering the small
subject sample size and the amount of missing data, it was
difficult to interpret effects of the dietary sodium
reduction treatment on premenstrual symptoms. When cycle
phases were averaged, however, subjects during the low-
sodium treatment showed lower overall levels of anxiety
than during baseline cycles. In addition, subjects during
the low-sodium treatment showed overall cycle weight
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decreases and a tendency toward lower systolic blood
pressure as compared with baseline.
Subjects
A total of 46 subjects participated in the initial
interview and completed all of the initial interview ques-
tionnaires. After deciding that the study would be too
time consuming, ten women elected not to continue. For a
variety of reasons, some personal and some involving
specific objections to the study itself, a number of
subjects chose to drop out at different points throughout
the study. A few women, for example, experienced
unexpected family or job crises which made it necessary
for them to drop out. When baseline cycles were completed,
some women with rigorous dietary principles couldn't
continue because of their objections to the capsules:
the placebo capsules contained dextrose, and the gelatin
casings of the capsules contained animal substances. Three
volunteers dropped out before the end of their first
baseline cycle. Seven more subjects finished at least
one complete baseline cycle, but discontinued their
participation before the end of the second cycle. There
were twelve subjects who completed two baseline cycles and
either discontinued at that point or dropped out prior to
the end of the third cycle. Of the remaining 14 subjects,
ten agreed to take part in the sodium reduction study and
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completed the six full cycles. (Data from the other four
subjects, who did not take part in the sodium reduction
study, were used for other purposes and are not included
in the analyses for the present study.
)
In order to see whether there were notable differences
between subjects as a function of length of participation
in the study, subjects were divided into four groups for
comparative purposes (see Figure 1).
The four groups consisted of 1) subjects who took part
in the initial interview only, 2) subjects who began the
home record-keeping but dropped out before completing both
baseline cycles, 3) subjects who completed at least two
baseline cycles but did not continue beyond the third
cycle, and 4) subjects who completed the entire six cycles
of the study. For each group means and standard deviations
were computed for the age, weight, number of children,
length of menses, day of cycle on which the initial inter-
view was held, the three MAACL mood scales, and water
retention, depression, and anxiety for all three phases
of the cycle as recalled on the Moos MDQ Form A. A series
of t-tests showed no significant differences between any
groups on any of the variables (see Appendix L for a table
of means and standard deviations).
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Comparisons of Initial Interview and
Baseline Data
Thirty subjects completed at least one baseline cycle.
Their ages ranged between 21 and 36 years, with a mean of
28.2 years and a standard deviation of 4.1. Eight of those
subjects had children. In spite of prior research evidence
that premenstrual syndrome may worsen with childbearing
(Moos, 1977), no significant differences were found between
groups of women with and without children on any variable.
Recalled menstrual cycle symptoms as assessed in the
initial interview on the Moos MDQ Form A showed the
predicted patterns (see Table 1). The three scales most
relevant to the premenstrual as opposed to the menstrual
phase of the cycle were examined: water retention,
depression, and anxiety. The water retention scale score
was derived by averaging responses to the three symptom
items "weight gain," "painful or tender breasts," and
"swelling (e.g., abdomen, breasts or ankles)." The
depression scale score was the average of the three symptom
items "crying," "loneliness," and "depression (feeling sad
or blue)." For the anxiety scale score four symptom items
were averaged: "anxiety," "restlessness," "irritability,"
and "tension." T-tests showed all three scale scores to be
significantly higher premenstrually than for the rest of
the cycle or post-menstrually (see Table 2).
Correlations among the initial interview variables
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TABLE 1
Retrospective Menstrual Cycle Symptoms,
Moos Menstrual Distress Questionnaire, Form A
Menstrual
X SD X SD X SD
Water
Retention 2 .69 1.01 1 .39 .83 3.50 1.23
Anxiety 2 .92 1.13 2 .09 .91 3 .45 1.11
Depression 2 .75 1.24 1 .92 .84 3.11 1.20
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TABLE 2
T-tests. Premenstrual versus Post-menstrual PhasesMoos Menstrual Distress Questionnaire, Form A
'
t df
Water
Retention 9.54 45
.0001
Anxiety 7.33 45
.0001
Depression 6.91 45
.0001
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were computed. Age, children, and day of the cycle on
which the interview was conducted showed no significant
correlation with any of the MAACL mood scales or the Moos
menstrual cycle scales for any phase. Length of menses
(the average number of days of menstrual flow as reported
by subjects retrospectively), however, was significantly
correlated with the Moos retrospective (Form A) menstrual
cycle symptoms for some cycle phases (see Table 3).
Correlations with premenstrual symptom levels were
positive—the longer the menses the worse the symptom—and
correlations with post-menstrual phase symptom levels were
negative—the longer the menses the more symptom severity
subsided post-menstrually
. While not all of those
correlations with specific phase symptom levels were
significant, in all cases correlations with change scores
(premenstrual minus post-menstrual) were significant and
positive—the longer the menses, the worse the premenstrual
symptoms compared to post-menstrual.
Baseline data from the first two cycles of home
record-keeping were examined both for comparisons with
initial interview variables and for comparisons with
treatment and placebo effects. In order to analyze the
daily record-keeping data for the baseline period as well
as for the four treatment and placebo cycles, certain
criteria were established for inclusion of data. Subjects
had been instructed to complete four sets of three-day
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TABLE 3
earson Correlation Coefficients, Reported AverageLength of Menses, and the Moos Menstrual DistressQuestionnaire, Form A Scales
Length of Menses (n=40)
Water Retention
Premenstrual r = .32 £ < .023
Post-menstrual r = -.17 £ < .240
Change : Premenstrual
minus post-menstrual r = .32 £ < .024
Anxiety
Premenstrual r = .26 £ < .056
Post-menstrual r = -.22 £ < .088
Change : Premenstrual
minus post-menstrual r = .39 £ < .006
Depression
Premenstrual r = .16 £ < .159
Post-menstrual r = -.38 £ < .008
Change: Premenstrual
minus post-menstrual r = .44 £ < .002
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home record-keeping packets per cycle: one set each during
the menstrual phase, follicular (post-menstrual) phase,
luteal phase, and premenstrual phase. Because the
scheduling of the home record-keeping was based on
subjects' estimates of their cycle length, the timing of
the actual record-keeping was inaccurate whenever a subject
did not begin menstruating on or near the predicted date.
Given the fact that the premenstrual phase was the focal
part of the cycle in this study, it was the premenstrual
record-keeping phase that was used to establish cycle
validity for purposes of data analyses. In fact, the
accuracy of the premenstrual phase scheduling turned out
to be the most variable. The menstrual and post-menstrual
(follicular) phases were determined by the actual onset
of menstruation, so that their scheduling accuracy was
extremely high. The luteal and premenstrual phase
schedules, however, were derived by counting back from
the predicted onset of the next menses. In order to make
sure that only valid premenstrual data were used in data
analyses, the following criterion was set: cycle data
were included only if a subject began her three-day
premenstrual record-keeping packet seven days or less
(up to three days) prior to the onset of menstruation.
Likewise, physiological data collected from office visits
(weight and blood pressure) were included only if the
premenstrual visit occurred within a week prior to the
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onset of menstruation.
Out of the 33 subjects completing at least one base-
line cycle, 23 subjects had valid home record-keeping data
for the first baseline cycle, and, 17 subjects had valid
home record-keeping data for the second baseline cycle.
Nineteen subjects had valid office visit data for the first
baseline cycle and 14 subjects had valid office visit data
for the second baseline cycle. Of these subjects, 12 had
valid home record-keeping data for both baseline cycles,
and nine subjects had valid office visit data for both
baseline cycles.
Comparisons were made of the Moos menstrual cycle
symptoms for the two baseline cycles (22 subjects in the
first cycle, 16 subjects in the second cycle) with the same
symptoms recorded retrospectively in the initial interview.
The only symptom scale for which the retrospective and
daily measures showed parallel patterns of significant
premenstrual change was the water retention scale. The
other Moos measures did not show the expected changes
for either baseline menstrual cycle (see Table 4).
There were few other consistent menstrual cycle
changes observed in either baseline cycle (see Table 5).
None of the MAACL mood scales showed significant worsening
premenstrually for either cycle. For the first cycle there
was a significant weight gain premenstrually, but for the
second cycle weight gain was not significant. For the
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first cycle premenstrual increase in systolic blood
pressure approached significance, but showed no change in
the second cycle. Subjects' food records showed no cycle
change in either salt intake or total food intake for the
first cycle, but an increase in premenstrual total food
intake approached significance in the second cycle.
Pearson correlation coefficients for cycle symptoms in like
phases of the retrospective Moos MDQ Form A and the Moos
daily MDQ Form T for both the first and second cycles are
shown in Appendices M-0. Correlation coefficients for
Moos daily MDQ symptoms in like phases of the two baseline
cycles are shown in Appendices P-R.
The inconsistency of the symptom patterns reflects
the high and varying levels of both between-subject and
within-subject variability. Estimates of between- and
within-subject variability were calculated for all home
record-keeping data and for the physiological data, using
the two baseline cycles (see Table 6). For the MAACL mood
scales in Table 6, it will be noted that there are blanks
for some of the between-subject estimates. These omissions
occurred when calculations resulted in standard deviations
with negative values. This statistical anomaly indicates
that the between-subject variability was very small in
relation to the within-subject variability for those
particular measures, so that the estimation procedures used
in partitioning the variability led to negative estimates
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of standard deviations. For the physiological variables
no measures were taken for the menstrual phase; therefore
those columns have been left blank.
Dietary Sodium Treatment Data
Ten subjects took part in and completed the entire
dietary sodium reduction study: two baseline cycles plus
two cycles each of treatment (lowered dietary sodium) and
placebo (replaced dietary sodium). However, after applica-
tion of the criteria described above to determine cycle
phase validity for the home record-keeping and office visit
data, it was found that there was a considerable proportion
of invalid or missing data (see Table 7). Because of the
amount of missing data and the small number of subjects,
cross-over or order effects could not be determined;
therefore placebo phases for all subjects were combined
for analyses, as were treatment phases.
An overview of the experimental data was obtained by
calculating adjusted averages of all variables (see
Tables 8 and 9). The adjusted averages were obtained by
replacing missing data for each particular cycle phase
with the overall mean for that phase within a given
experimental division: baseline, placebo, or treatment.
The variable showing the clearest change from base-
line to placebo and treatment is salt intake, which was
substantially larger for baseline than for the other two
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TABLE 7
Valid Menstrual Cycle Data for Sodium Reduction Subjects
Home Record-keeping Data
Baseline Placebo Treatment
Subject Cycle Cycle Cycle Cycle Cycle CycleNumber 1 2 i 2 12
^ ^ + +
2 + + + + + +
3 +
4 +
5 + + + + +
6 + + + + +
7 + +
8 + + + +
9 + + + + +
10 + + + + + +
Office Visit Data ( Physiological Measures )
Baseline Placebo Treatment
Subject Cycle Cycle Cycle Cycle Cycle Cycle
Number 12 12 12
1 + + +
2 + + + + + +
3 + + + + +
4 + +
5 + + +
6 + + + +
7 + +
8 + + +
9 + + + + +
10 + + + + + +
Plusses indicate cycles with valid data; cycles with
invalid data were left blank.
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experimental divisions. This finding indicates that
according to subjects' self-report food check lists,
they did adhere to the modified low-sodium dietary
instructions. With the exception of the Moos depression
measure, both MAACL and Moos self-report measures show the
expected curve for the baseline period, with premenstrual
increase in negative symptom levels. Physiological and
food measures show the same baseline curve, but with
premenstrual increase being very slight. The mood measures
and subjective water retention appear to show a similar
curve for placebo and treatment cycles as well, with little
apparent difference from baseline patterns. The food
measures—both salt intake and total food intake—show an
overall drop during both placebo and treatment. This
pattern indicates that as subjects complied with the
dietary reduction of salt, their total food intake
decreased slightly. Weight and systolic blood pressure
show lower overall cycle levels for treatment and placebo,
without premenstrual increases
.
Because the amount of missing data precluded more
elaborate analyses of treatment effects, a series of
paired t-tests was performed for all home record-keeping
variables, comparing baseline cycle 1 with treatment
cycle 2, and placebo cycle 2 with treatment cycle 2.
(These cycles of each experimental division were chosen
because they had more valid subject data than did the other
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cycles of each experimental division.). Table 10 shows
results for the premenstrual phase of the selected cycles.
While the MAACL hostility scale shows an increase which
approaches significance from baseline to placebo, the only
significant premenstrual change is a decrease in self-
reported salt intake for both placebo and treatment
divisions—again, confirming subjects' compliance with the
sodium reduction diet. Table 11 shows results of paired
t-tests comparing within-cycle change scores. No
differences among experimental divisions were found. The
majority of change scores for all divisions show the
premenstrual phase to be higher than post-menstrual for
most variables (see also Table 8). Negative t-values in
column 3 of Table 11 indicate that the change scores during
treatment were consistently but not significantly larger
than were placebo change scores.
Table 12 shows results of paired t-tests when each
cycle was averaged over all four phases (see Figures 2-4).
Highly significant differences in salt intake confirm the
success of the dietary manipulation. A slight decrease in
food intake which accompanied the lowered sodium consump-
tion approached significance during the treatment division.
A surprising placebo effect is indicated by the significant
decrease over baseline in the MAACL hostility scale. The
MAACL anxiety scale shows a significant treatment effect;
the Moos anxiety scale shows a parallel effect which
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approaches significance. There is also a placebo effect
on both anxiety scales which approaches significance.
Because cycles with valid office visit (physiological)
data were somewhat different than home record-keeping valid
cycles (see Table 7), the cycles selected for paired
t-tests of physiological measures were different than
cycles used in Tables 10-12. Table 13 shows the results
of paired t-tests for the physiological variables for all
subjects with valid cycle data. The only effect approach-
ing significance was a premenstrual decrease in systolic
blood pressure during treatment.
There was one subject who lost over twenty pounds
between the beginning and end of the study. Because
this extreme weight loss case could obscure more siibtle
fluctuations or treatment effects on other subjects, the
paired t-tests for the physiological data were recalculated
without that particular subject (see Figure 5). This sub-
ject had valid office visit data for only one treatment
cycle in addition to baseline cycle. Therefore the dele-
tion of her physiological data affected only the paired
t-tests comparing baseline and treatment (see Table 14).
Without the extreme case, a significant treatment effect
of weight loss is shown when cycle phases were averaged.
A decrease in cycle average systolic blood pressure
approached significance.
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TABLE 14
Paired T-tests. Physiological Variables(Excluding Extreme Weight Loss Subject)
Baseline and Treatment
t Value (df = 3)
Premenstrual
1.910
Blood Pressure
Systolic 1.950
Diastolic 0.210
Change: Premenstrual
minus Post-menstrual
Weight 0.130
Blood Pressure
Systolic 0.310
Diastolic
-0.210
Cycle Average
Weight 3.350**
Blood Pressure
Systolic 2.780*
Diastolic -1.620
*£ < .10
**£ < .05
CHAPTER IV
DISCUSSION
\
Smnmary
The purpose of this study was two-fold. First, sub-
jects kept daily home symptom and dietary records for a
two-cycle baseline period in order to document patterns of
menstrual-cycle symptoms, with a specific focus on the
premenstrual syndrome. Second, a reduced level of dietary
sodium was instituted so that its effect on the premen-
strual syndrome could be tested.
Baseline patterns that emerged from the daily record
data corroborated subjects' retrospective reports of some
premenstrual symptoms but not others. Subjective experi-
ence of water retention was the most consistently reported
premenstrual symptom, appearing both in the retrospective
measure and in both baseline cycles. Premenstrual mood
symptoms—increased anxiety and depression— were reported
retrospectively, but were not confirmed for either base-
line cycle. Physiological measures—weight and blood
pressure—increased premenstrual ly in only one of the two
baseline cycles, and then, for systolic blood pressure,
only marginally.
Conclusions drawn as to the effects of the
66
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experimental manipulation must be considered tentative
because of the very small number of subjects with valid
menstrual cycle data. None of the hypotheses set forth
in this study was confirmed; that is, reducing dietary
sodium appeared to have no effect on any premenstrual
symptoms, either measured directly or as a change score
(premenstrual minus post-menstrual). The sodium reduction
treatment did appear to affect levels of some of the
symptoms when overall cycle averages were examined. Weight
was significantly lower as compared to baseline weight
during the treatment cycles but not during placebo cycles.
One anxiety measure—the MAACL anxiety scale—was signifi-
cantly lower than baseline during treatment cycles. The
same measure approached significance during placebo cycles
while the Moos anxiety scale showed a decrease which
approached significance during both placebo and treatment.
Subjects
No differences appeared on initial interview variables
as a function of how long subjects actually participated in
the study. The issue of the population sample characteris-
tics remains an important one, however, both in terms of
practical considerations for conducting future research
projects, and because of the question of the genraliza-
bility of any conclusions that might be drawn. Although
subjects were paid in the current study, the amount of
68
payment apparently was too low to provide a strong impetus
for them to continue through the entire six months. in a
study such as this, with very little in the way of
external motivations, the self-selected subject sample is
likely to be unrepresentative of the general population.
In fact, in the present study, an interest in women's
issues seemed to be more of a motivating factor for many
subjects than extreme premenstrual symptoms. Although most
subjects reported regular experiences of premenstrual
symptoms (as noted in the responses to the retrospective
Moos questionnaire), few women claimed to have severely
debilitating symptoms. One exception was a woman who
suffered severe premenstrual depression and bloating. She
dropped out early in the study when she became discouraged
with the long baseline period and with the idea that she
might then be given a placebo which wouldn't be likely to
help her.
Interviewers noted that most subjects who did not drop
out early did have a special interest in the effects of
diet and life-style on health. A number of the women were
vegetarians or had other special dietary concerns, and
several women were interested in exercise as well as in
diet. One of those women was eager to continue in the
study, but never started menstruating for her second
baseline menstrual cycle—in all likelihood because of a
significant increase in her daily running distance. Other
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kinds of stress—not necessarily with obvious physical
manifestations—led to several drop-outs. One woman's
father died, another reported an unexpected job change,
one marital relationship underwent a crisis.
Not unexpectedly, a large number of subjects dropped
out of the study at the end of the second baseline cycle
or shortly after the beginning of the experimental phase.
A number of these drop-outs simply decided that they didn't
want to eliminate salty foods from their diets. Others
objected to the capsules, which were, indeed, rather
formidable: they were about three-fourths of an inch in
length, and subjects had to take eight of them per day.
Atlhough subjects had been assured that the capsules did
not contain any drugs but rather a "dietary supplement,"
nevertheless, some subjects felt too uncomfortable about
them to be willing to continue the daily swallowing of so
many large, mysterious capsules. One subject, a nurse who
was extremely interested in participating, finally dropped
out after reporting repeated bouts of nausea after taking
the capsules. This was the only case where any side effect
from the capsules was reported; interestingly, it turned
out that this subject had been assigned to the treatment
group, so that she was reacting to capsules containing
dextrose
.
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Comparisons of Initial Interview and
Baseline Data
Subjects' retrospective reports of their menstrual
cycles showed the expected worsening of mood and water
retention symptoms premenstrually
. Although Moos (1977)
has reported that premenstrual syndrome may worsen with
age and childbearing, the current study showed no correla-
tion between age or children and reported symptom severity.
However, in this study women over thirty were somewhat
underrepresented (12 out of 46), as were those with
children (eight out of 46), so the effects of these factors
could not be adequately tested. The one initial interview
variable that did correlate significantly with severity of
all three premenstrual symptoms was length of menses.
This intriguing finding may simply reflect a tendency for
some subjects to emphasize overall severity of menstrual
symptoms. However, length of menses did not correlate
with menstrual phase ( as opposed to premenstrual ) symptoms
except for water retention. There may, therefore, be some
real connection between the premenstrual syndrome and the
length of menstrual flow. Further research is needed to
shed light on this question.
One important factor which hampered this study was
the amount of variability found in length of cycle. Most
subjects initially reported that their cycles were quite
regular; in fact, subjects who reported irregular cycle
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lengths were disqualified from participation in the initial
screening. Yet it was not unusual for individual subjects'
cycles to vary from their own "norm" by as much as a week,
or even more, for at least one or two cycles out of the
six cycles followed in this study. The variant cycles
were no more likely to be one of the treatment or placebo
as opposed to baseline cycles, so it does not appear that
the dietary change or capsule supplements had any effect
on cycle length. In any case, a considerable amount of
information was unusable because of variable cycle length.
The problem of cycle length variablility could be
overcome in future research by the use of a more regular
method of home record data collection, rather than the
four discrete sets of three-day packets based on estimates
of cycle length. If subjects were to record their data
every other, or even every day, then cycle phases could be
determined retrospectively by counting back from the onset
of menstruation, and the appropriate data sets could be
used. Such a method would have an additional advantage
over the current study, whose four data packets served to
highlight subjects' consciousness of different cycle
phases. If women routinely filled out the data forms
every day or every other day, they would be less likely to
be self-conscious and therefore biased about which part of
their cycle they were experiencing. The primary disadvan-
tage of that method, and the reason it wasn't used in the
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current study, is the problem of subjects' willingness to
cooperate when asked to fill out so many forms so often.
Most subjects, however, in post-study conversations, s^tated
that they wouldn't object to filling out the questionnaires
more frequently, since they were not unduly time-consuming.
In addition to cycle length variability, variability
of symptom patterns also posed a problem. Considerable
between-subject variability had been expected, but the
within-subject variability was even greater than expected.
Subject inconsistency across the two baseline cycles not
only made it difficult to interpret subsequent treatment
effects, but also posed a problem in understanding
subjects' initial, retrospective reports of symptom
patterns. It is possible that in the retrospective symptom
reports, subjects were automatically "averaging" their
cumulative experience of menstrual cycle symptom patterns.
It is also possible that their retrospective reports merely
reflected the cultural expectation for premenstrual
symptoms. The latter explanation seems unlikely, however,
since subjects could just as easily have followed the
culturally expected pattern of symptom reporting in their
home records, since they were aware of which cycle phase
they were going through for each three-day data set. The
fact that they did not simply follow an expected norm in
their daily records suggests that subjects do in fact
experience considerable variation in their cycle patterns
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from month to month.
There are a number of factors that may contribute to
high within-subject menstrual cycle symptom variability.
Environmental stresses, both positive and negative, have
an immediate impact on many of the relevant variables—
especially mood measures. While it wasn't possible in
this study to quantify stressors in terms of their impact,
subjects did give brief qualitative reports of perceived
stressors as part of their daily records. It was clear
that depression and anxiety measures were sensitive to
obvious stressors, such as an argument with a spouse or
lover, or job-related stress. It is easy to see how daily
environmental occurrances could in the short run overshadow
the more subtle, though equally real, effects on mood of
cyclic hormonal changes. Baseline record-keeping data
would have to be collected for many more cycles than two
in order for a consistent cyclic pattern to emerge over
and above daily fluctuations caused by a variety of
life events.
Dietary and physiological data were undoubtedly
affected by environmental events as well. Salt and total
food intake did not show significant premenstrual
increases, expect for a tendency during the second cycle
for food consumption to increase premenstrually . In other
words, Dalvit's (1981) strong evidence of premenstrual
increase in food consumption was only marginally and
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inconsistently confirmed. Unfortunately, for many subjects
the first baseline cycle and in some cases both baseline
cycles coincided with the Thanksgiving-Christmas-New Year
holiday season, a time when food consumption for many
people is thrown off its usual course. Another possible
explanation for the failure to find expected menstrual
cycle dietary patterns, as well as for the inconsistent
mood patterns, may have involved the fact of the record-
keeping itself. A number of subjects in fact commented
that they thought their increased awareness of mood and
eating patterns resulting from the record-keeping actually
did influence their affect and their behavior. Again,
more than two baseline cycles may be necessary for behavior
changes resulting from self-observation to stablize.
In addition to external factors affecting variability,
some within-subject variability may result from varying
patterns of monthly hormone fluctuations—variations quite
possibly influenced in turn by environmental or seasonal
factors. Some of these monthly hormonal pattern
differences could result in changing levels or types of
menstrual symptoms, or in symptoms occurring at different
times. A number of subjects noted that they might experi-
ence premenstrual symptoms any time during the two weeks
between ovulation and menstruation. In this study earlier
luteal phase symptoms were not included in statistical
analyses, but it might be important to take the entire
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premenstrual time period into account in future research.
Dietary Sodium Treatment Results
The ten subjects who participated in the experimental
manipulation for the last four cycles of the study were
all interested in diet and health issues as well as in the
premenstrual syndrome. It is important to note that their
initial dietary patterns were probably not representative
of the population at large, either in sodium content or in
other respects, although no normative comparison data were
available to make such an assessment. An important aspect
of the double-blind design was the use of capsules to
replace dietary sodium in the placebo phase. Yet for the
subject population participating in this study, the daily
four grams of salt consumed in capsule form may have
replaced more salt in subjects' diets than was actually
eliminated through dietary change. On the other hand,
the possibility that subjects did not comply with the
instructions to take eight capsules per day must also be
considered. The effect of subjects taking fewer than the
eight capsules per day would differ according to the
experimental phase in question. Fewer capsules during the
treatment phase would have no effect, since those capsules
only contained dextrose. Fewer capsules during the placebo
phase, however, would of course mean that subjects were not
in fact replacing their dietary sodium, and, depending on
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their actual levels of sodium and the number of capsules
omitted, they might tend to approximate the treatment phase
rather than the placebo phase in dietary salt consumption.
Thus, without independent corroboration of actual salt
consumption (such as measures of urinary sodium levels),
possible placebo effects in this study cannot be distin-
guished from non-compliance effects in interpreting the
lack of differences between treatment and placebo results.
The only clear difference between baseline and
treatment phases appeared when overall cycle averages were
compared: anxiety, weight, and, more tentatively, systolic
blood pressure showed lower levels during treatment than
baseline. Part of the reason for this finding, it should
be pointed out, is that averaging the four cycle phases
eliminates a certain amount of variability—an important
factor especially in analyses using so few subjects.
Nevertheless these findings have important implications:
it may indeed stand to reason that reducing dietary sodium
does have an absolute effect on anxiety, weight, and blood
pressure irrespective of the menstrual cycle. Although
evidence as to the effectiveness of dietary salt reduction
as a treatment for hypertension is controversial, Tuthill
and Calabrese (1981b) have provided evidence showing that
in normotensive populations, systolic blood pressure levels
are related to sodium consumption. The evidence from the
present study, though inconclusive because of missing data
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and small subject sample size, corroborates the findings
of Tuthill and Calabrese. The additional evidence in this
study that reduced salt intake may be related to lower
levels of anxiety also has far-reaching implications for
the treatment and/or prevention of hypertension. it has
often been postulated that anxiety levels may be an
intermediary link in the development and maintenance of
hypertension in susceptible individuals. Direct evidence
such as the findings in this study can lead to increased
understanding of the elements of hypertension—which in
turn can further the development of more comprehensive
treatment approaches.
Recommendations
Research on the relationship between dietary sodium
and the menstrual cycle has widespread implications for
many issues in addition to premenstrual syndrome, including
hypertension, eating behavior, and the overall health
concerns of women. Yet because of the difficulties
involved in doing this research, many questions remain to
be clarified. Considerable financial and institutional
resources are necessary to insure adequate sample sizes
and experimental time periods. Length of time is particu-
larly important, as was seen in the present study, because
of high within-subject variability. Many months would be
required to document baseline patterns that are subject to
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the effects of seasonal and environmental factors, as well
as endogenous variations. Subjects should be matched for
age, children, severity and type of symptom, and even for
dietary characteristics. Methods for assuring subject
compliance with experimental manipulations must be
developed. As the role of dietary sodium in relation to
menstrual cycle phenomena is clarified, questions about
additional factors, such as other nutritional elements,
can also be addressed.
In summary, the surprising discrepancy in the current
study between baseline and retrospective menstrual cycle
patterns emphasizes the need for undertaking rigorous
longitudinal research in order to clarify the elusive
nature of the premenstrual syndrome. Furthermore, the
overall effect on anxiety of reducing dietary sodium
clearly establishes a connection between mood states,
dietary factors, and health concerns that demands continued
investigation
.
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APPENDIX A
INSTRUCTIONS FOR A MODERATELY LOW-SODIUM DIET
Most foods already contain varying amounts of salt
so that even if you add no salt to your food and avoidhighly salted foods you are getting plenty of sodium.
1. Add no salt to your cooking, or to your food at the
table
.
2. Avoid the following foods, which are high in salt
content
:
Ham
Corned beef
Bacon
Processed meats (sausage, salami, bologna, etc.)
Pickles
Relishes
Catsup
Mustard
Soy sauce
Commercial salad dressings
Olives
Sauerkraut
Canned or dried soups
Cheese (including cottage cheese)
Salted snacks (crackers, pretzels, chips, nuts)
Restaurant food, especially "fast- food" restaurants
Canned fish
Pre-prepared processed foods (frozen dinners, pizza
fried chicken, canned pork and beans, etc.)
3. Avoid antacid preparations, such as Alka-Selzer; also
some other common drugs contain sodium. Check with
your druggist or physician.
Within a week or two you will find yourself becoming
accustomed to the natural tastes of many foods, and salty
foods will be distasteful.
There may be occasions when you find it unavoidable
to have some of the above listed foods. Don't worry about
it, but try to avoid the foods as much as possible.
Let us know about how you are doing, and if there are
any questions or problems
.
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APPENDIX B
INFORMED CONSENT FORM
I understand that in this study I will be asked tokeep a regular record of, my premenstrual symptoms, moods,dietary intake, and activity level, and that I will cometo Tobm Hall three times a month to have my weight, bloodpressure, and home record-keeping checked. I understandthat after a two month baseline period I may be asked to
make some changes in my diet and/or take some daily
capsules which may contain either a dietary supplement or aplacebo (inert substance), which may or may not affect my
premenstrual symptoms. I understand that all of my records
and all other experimental data will be kept completely
confidential and anonymous.
I understand that the dietary supplement and placebo
present no risk to my health, I also understand that if I
participate for at least four months I will receive an
agreed upon sum of money. I have been informed that I may
withdraw my consent and withdraw from the study at any time
without penalty. I understand that although during the
study I will not be told what the dietary supplement is or
whether I will be taking the supplement or the placebo, at
the conclusion of the study I will be given all of this
information as well as any other information I wish to have
about the methods and hypotheses of the study.
Date Signature
APPENDIX C
SAMPLE OF 2 8-DAY MENSTRUAL CYCLE
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APPENDIX D
INITIAL INTERVIEW QUESTIONNAIRE
Date Name
Interviewer Subject #
Phone #
Today's Blood Pressure Number of Children
Occupation Education Level
Approximate Income Living Situation
Please circle the number which best describes you.
1. What is your appetite usually like?
extremely
satiated
moderately
satiated
slightly
satiated
4
neither
hungry nor
satiated
slightly
hungry
moderately
hungry
extremely
hungry
2. What is your usual activity level?
extremely
inactive
moderately
inactive
slightly
inactive
4
neither
active nor
inactive
5 6 7
slightly moderately extremely
active active active
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3. What is your usual caffeine intake per day? Specify
cups of coffee, tea, cans of soda, candy bars, etc.
4. List any recent events (within the last month) which
might be considered stressful, i.e., marriage,
separation, births, deaths, promotion, demotion,increase in income, decrease in income, etc.
Please list any medications that you use, including
over-the-counter drugs, street drugs, and diet pills
How often do you use each listed above?
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APPENDIX E
MULTIPLE AFFECT ADJECTIVE CHECK LIST
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Below you will find words which describe different kindsof moods and feelings. For each word, decide whSher ornot It describes how you feel most of the time If itdoes circle it; if it doesn' tT^n"^ ii?k-i^at all. someof the words may sound alike, but we want you to mark allthe words that describe your feelings. Work rapidly.
1
.
active 26. cool 51. furious
2 . adventurous 27. cooperative 52. gay
3 . affectionate 28. critical 53. gentle
4 afraid 29. cross 54. glad
5 agitated 30. cruel 55. gloomy
5 . agreeable 31
.
daring 56. good
7 . aggressive 32 . desperate 57. good-natured
8 . alive 33 . destroyed 58. grim
9 alone 34. devoted 59. happy
10 amiable 35. disagreeable 60. healthy
11 amused 36. discontented 61. hopeless
12 angry 37 discouraged 62. hostile
13 . annoyed 38. disgusted 63. impatient
14 awful 39 displeased 64. incensed
15 bashful 40 energetic 65. indignant
16. bitter 41. enraged 66. inspired
17. blue 42. enthusiastic 67. interested
18. bored 43. fearful 68. irritated
19. calm 44. fine 69. jealous
20. cautious 45. fit 70. joyful
21. cheerful 46. forlorn 71. kindly
22. clean 47. frank 72. lonely
23. complaining 48. free 73. lost
24. contented 49. friendly 74. loving
25. contrary 50. frightened 75. low
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76. lucky 95. reckless 114. tender
77. mad 96. rejected 115. tense
78. mean 97. rough 116. terrible
79. meek 98. sad 117. terrified
80. merry 99. safe 118. thoughtful
81. mild 100. satisfied 119. timid
82. miserable 101. secure 120. tormented
83. nervous 102. shaky 121. understanding
84. obliging 103. shy 122. unhappy
85. offended 104. soothed 123. unsociable
86. outraged 105. steady 124. upset
87. panicky 106. stubborn 125. vexed
88. patient 107. stormy 126. warm
89. peaceful 108. strong 127. whole
90. pleased 109. suffering 128. wild
91. pleasant 110. sullen 129. willful
92. polite 111. sunk 130. wilted
93. powerful 112. sympathetic 131. worrying
94. quiet 113. tame 132. young
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APPENDIX F
MENSTRUAL DISTRESS QUESTIONNAIRE
(Form A)
Name Marital Status
Number of Children
Today's Date Occupation
Write the approximate dates of your most recent menstrual
period (flow) in the space marked "A" below. Then
write the dates of the menstrual period which preceded
the most recent one in the space marked "D"
.
^^om other times during
to most recent cycle
D C
most recent flow
week before most from
recent flow to
B A
On the next two pages is a list of symptoms which women
sometimes experience. Please describe your experi-
ence of each of these symptoms during the three
different time periods listed below:
Col. 1 during your most recent menstrual flow (the
dates delineated by area A on the diagram
above )
,
Col. 2 during the one week before your most recent
flow (area B on the diagram).
Col . 3 during the remainder of your most recent
menstrual cycle (area C).
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Note: The answers you put in columns 1, 2, and 3
should be accurate for your experience specificallyduring your most recent menstrual cycle. Please do
not simply report yoar general experience. Alsoplease report an^ experience of these symptoms
whether or not they seem to you to be related to your
menstrual cycle.
Copyright: Rudolf H. Moos, 1968, 1977
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For each answer choose the descriptive category listedwhich best describes your experience of that symptomduring that time. Write the number of that de^^ip!!!tion in the space provided. Even if none of thedescriptions are exactly correct, choose the one thatbest describes your experience. Do not leave anyblank spaces.
Descriptive Categories
1 - no experience of symptom
2 - barely noticeable
3 - present, mild
4 - present, moderate
5 - present, strong
6 - acute or partially disabling
1. 2. 3.
most week remainder
recent before of cycle
flow (A) (B) (C)
1. Weight gain
2. Insomnia
3. Crying
4. Lowered school or
work performance
5. Muscle stiffness
6. Forgetfulness
7. Confusion
8
. Take naps or
stay in bed
9 . Headache
10. Skin Disorders
11. Loneliness
12. Feelings of Suffocation.
13. Affectionate
14. Orderliness
15. Stay home from
work or school
16. Cramps (uterine or
pelvic )
17. Dizziness or faintness..
18. Excitement
19. Chest pains
20. Avoid social activities.
21. Anxiety
22. Backache
23. Cold sweats
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1- 2. 3.
most week remainder
recent before of cycle
flow (A) (B) (c)
24. Lowered judgment
25. Fatigue
26. Nausea or vomiting
27. Restlessness
28. Hot flashes
29. Difficulty in
concentration
30. Painful or tender
breasts
31. Feelings of well-being..
32. Buzzing or ringing
in ears
33. Distractable
34. Swelling (e.g., abdomen,
breasts or ankles)
. . .
.
35. Accidents (e.g., cut
finger, break dish) . .
36. Irritability
37. General aches and pains.
38
. Mood swings
39. Heart pounding
40. Depression (feeling
sad or blue )
41. Decreased efficiency....
42
. Lowered motor
coordination
43
.
Numbness or tingling
in hands or feet
44. Change in eating habits.
45. Tension
46 . Blind spot or
fuzzy vision
47. Bursts of energy or
activity . .
In what ways, if any, was your most recent menstrual cycle
unusual?
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APPENDIX G
FOOD FREQUENCY LIST
DATE
SUBJECT NUMBER
Day of Cycle
f^^? serving size as a rating of "l". Foreach food Item listed below, please list the number oftimes you ate that item today. Specify if veg^Ls orsoups are canned with a check. yci.cu;xes
MILK
whole
skim
lowfat
nonfat dry
evaporated
CREAM
half & half
sour
PIZZA, with tomato and cheese
YOGURT
plain
vanilla
lemon
fruit types
CHEESE
processed
Cheddar
blue cheese
ricotta
roquefort
Swiss
cottage
MEAT
roast beef
steak
corned beef
meatloaf
hamburg
veal
MEAT (continued)
lamb
tongue
brains
heart
kidneys
liver
pork
goose
venison
CHICKEN
liver
heart
kidneys
TURKEY
liver
heart
kidneys
PREPARED MEATS
hot dogs
bologna
boiled ham
salami
liverwurst
Vienna sausages
deviled ham
sausage
Italian links
kielbasa
bacon
chicken pie
meat pie
turkey pie
chicken salad
ham salad
VEGETABLES CANNED
bean sprouts
baked beans w/ pork and tomato
~
chickpeas
lentils ~
soybeans ~
tofu
~
chili
artichokes
asparagus
avacado
bamboo shoots
VEGETABLES (continued)
black beans
pinto beans
wax beans
lima beans
kidney beans
beets
broccoli
brussel sprouts
cabbage
carrots
carrot juice
cauliflower
chives
celery
chard
corn
eggplant
miso
natto
mustard greens
kale
kohlrabs
leeks
mushrooms
onion, dehydrated
green peas
baked potatoes
boiled potatoes
mashed potatoes
hashbrowns
french fries
potato chips
scalloped potatoes
pumpkin
sauerkraut
winter squash
sweet potatoes
spinach
tomato puree
tomato juice
vegetable juice
mixed vegetables
Greek olives
green olives
parsnips
dill pickles
sweet pickles
pickle relish
baker's yeast
torula
JUICES
orange
grapefruit
apricot
pineapple
prune
V-8
FISH
bass
bluefish
tuna (canned)
carp
clams (canned)
clams
crab
anchovies
eel
haddock
herring
flounder
kelp
fishsticks
lobster (canned)
lobster
scrod
scallops
snapper
swordfish
shrimp (canned)
shrimp
mackerel
oysters (canned)
oysters
perch
pike
pollock
sardines
FRUITS
apricots
dried
water packed
syrup packed
BREADS/CEREALS
whole wheat
dark rye
hard rolls
soybread
potato bread
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BREADS/CEREALS ( continued
)
waffles
granola
oat flakes
wheaties
wheat flakes
bulgar
bran
brewer's yeast
wheat germ
buckwheat
breadcrumbs
corn meal
salted crackers
wheat thins
ritz
saltines
pretzels
rice w/ salt
NUTS & SEEDS
almonds
brazil nuts
salted peanuts
fresh chestnuts
salted mixed nuts
hazel nuts
pecan nuts
sunflower seeds (salted)
English walnuts
peanut butter
popcorn (w/ salt)
CANNED ?
asparagus
bean w/ pork
beef broth
celery
chicken
clam chowder
meat and vegetable
~
minestrone
mushroom ~
onion
split pea
~
tomato
veg-veg
other
PASTA & CASSEROLES
macaroni and cheese
spaghetti sauce, tomato,
and cheese
ravioli w/ tomato sauce
Lasagna
chop suey
other
DRESSINGS
butter
Italian dressing
blue cheese dressing
gravy
catsup
SPICES
salt
soy sauce
worchestershire sauce
COOKIES
brownies
chocolate chip
oatmeal
peanut butter
sugar
other
CANDY
chocolate bar w/ almonds
chocolate mint
chocolate other
caramel
fudge w/ nuts
hard candy
jelly beans
M & M's
peanut brittle
other
DESSERTS
ice cream
ice milk
sherbet
yogurt
popsicle
cones
custard
pudding
PIES
lemon meringue
pecan
pumpkin
pie crust
gingerbread
chocolate frosting
other
FLAVORINGS
ovaltine
chocolate syrup
chocolate powder
Quik
BEVERAGES
hot chocolate
tea
coffee (caffeinated)
cola
sodas, other
alcoholic
beer
beer (lite)
sherry
liquer
wine
whiskey
other hard liquors
other
JAMS & JELLIES
blackstrap molasses
brown sugar
sugar
jam/jelly
honey
syrup
other
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APPENDIX H
LIFE HISTORY AND HEALTH QUESTIONNAIRE
1. Age sex Height Weight
VonlU^to HU?" !!!!:^ underweight, what would
2. Marital status (circle one): single, engaged
married, separated, divorced, widowed, remarriedliving with someone u xixcu,
3. Living situation (circle one): dorm (how many room-
f^^^s? ), apartment (with how many others"? )house (with how many others? )
4. Personal History: Date of Birth
Place of Birth
Siblings: Number of Brothers Ages:
Number of Sisters Ages: ~
—
Father: Living? if alive, give father's
present age
Deceased? If deceased, give his age at
time of death
Cause of death
Occupation Health
Mother: Living? if alive, give mother's
present age
Deceased? If deceased, give her age at
time of death
Cause of death
Occupation Health
Circle any of the following that applied during your
childhood/adolescence
:
Happy childhood Family problems
Unhappy childhood Drug abuse
Emotional/Behavior problems Medical problems
Legal trouble Alcohol abuse
School problems
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5. Family Health History (Circle any of the followingthat apply to you or members of your family and no-h^who had or has the problem):
^^i y, te
Thyroid disease
Kidney disease
asthma
neurological problems
infectious diseases
diabetes '
cancer
gastrointestinal disease
glaucoma
epilepsy
heart or circulatory problem
depression
emotional problems
addiction
obesity
__zzzzzzziin]mi~
allergy
"
6. Personal health
Describe any head injuries or loss of consciousness
you have had:
Describe any surgery you have had, and when
Describe any accidents or injuries you have had,
and when
Describe any serious illnesses you have had, and when
Describe any other health problems you have had
7. For each of the following, check the appropriate
column as it applies to you:
Moderately Very
Never Rarely Often Often
Marijuana
Tranquilizers
Sedatives
Aspirin
Cocaine
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Moderately Very
Never Rarely Often Often
Painkillers
Narcotics
Stimulants
Hallucinogens (LSD, etc.)
Stomach pain or discomfort
Diarrhea
Constipation
Allergies
Nausea
Vomiting
Insomnia
Work too hard
Loss of control
Suicidal attempts
Nervous tics
Concentration difficulty
Phobia
Lazy
Aggressive behavior
Crying
Temper outbursts
Headaches
Backache
Fatigue
Fitful sleep
Dizziness
Palpitations
Muscle spasms
Tension
Sexual disturbances
Tingling
Numbness
Tremors
Fainting spells
Hearing things
Skin problems
Visual disturbances
Hearing problems
Overeating
Poor appetite
Eat "junk foods
109
""'^rra^^Lf (Circle,.
9.
lunch dinner
10. Which is your heaviest meal of the dav^Breakfast lunch dinner
11. Do you regularly do without or skip any meal^If so, which? *- J • _
12. Do you regularly snack between meals or in theevening?
What are your typical snacks?
13. List the main foods you dislike and do not eat.
14. List your favorite foods (foods you would have diffi-
culty giving up).
15. Have you ever been on a diet?
How often? When?
What kind of diet(s)? ~
For how long? ~ ~ ~~
16. How often do you drink alcoholic beverages? (circle)
Never rarely a few times a week every day
What kind? wine beer mixed drinks
17. How much coffee do you drink per day? cups
What kind? cups brewed regular
cups brewed decaffeinated
cups instant regular
cups instant decaffeinated
How many soft drinks do you have per day?
What kind?
18. Do you eat chocolate regularly?
_
In what form? How much?
Other candy or sweets?
19. Do you eat refined, pre-packaged or highly processed
foods regularly? What kinds?
How much?
20. Describe any alergies you have to food or other
substances
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21. Do you smoke? What? How much?
22. How often do you catch colds or flu^ (circle
^
More often than 1/month less than l%onth, but
Three to 5/vear ^ "^^f^^ ^ 8/yearxn :o b y two or less per year
23. How many hours do you usually sleepWhat time do you usually go to sleep? ~What time do you usually wake up"^ ~
Do you have trouble going to sleep?
JnlTf^^ V?-^"" "^^^^^^ night and havetrouble falling asleep again"?
Do you wake up early and have trouble getting backto sleep? ^
Do you usually remember dreaming?
24. Activity:
During a typical waking day, how many (estimated hoursdo you spend:
sitting down?
^
standing up?
walking? ^ being active or exercising?
If you engage m activity or exercise on weekends or
other occasions describe:
how often? ~" ~ —
Ill
APPENDIX I
RECORD KEEPING QUESTIONNAIRE
Date Name
Interviewer Subject #
Phone #
Please circle the number which best describes you TODAY.
1. What was your appetite like today?
extremely
satiated
moderately
satiated
slightly
satiated
4
neither
hungry nor
satiated
slightly
hungry
moderately
hungry
extremely
hungry
2, What was your activity level?
extremely
inactive
moderately
inactive
slightly
inactive
4
neither
active nor
inactive
slightly
active
moderately
active
extremely
active
3. What is your usual caffeine intake per day? Specify
cups of coffee, tea, cans of soda, candy bars, etc.
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List any recent events within the last week whichmight be considered stressful, i.e., marriaae
separation, births, deaths, promotion, demotionincrease m income, decrease in income, etc
5. Please list any medications, over-the-counter druasstreet drugs, or diet pills that you have taken todiy.
How much of each of those listed did you take?
6. Did you crave a certain food today?
If yes, what food?
What time of day?
Did you eat the food?
How much did you eat?
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APPENDIX J
MULTIPLE AFFECT ADJECTIVE CHECK LIST, SHORT FORM
Below you will find words which describe different kinds of
moods and feelings. For each word, decide whether or notIt describes how you feel today
. If it does, circle it; ifIt doesn't, don't mark it at all. Some of the words may
sound alike, but we want you to mark all the words thatdescribe your feelings. Work rapidly.
1. active 22
.
**J . panicKy
2. adventurous 23 rll QTil ^AQ^H polite
3. afraid 24. F^^f5 T'Fii 1.!>w CI J_ JL poweriui
4. agreeable 25. fine 46
5. aggressive 26. forlorn 47
.
is ^ \^ ^ '
6. alive 27. frank 48 shalcv
7. alone 28. frightened 49 stubborn
8. amiable 29. gay 50 sufferincT
9
.
amused 30 CTOA.. S UXlK
10. angry 31. healthy 52. sympathetic
11. awful 32. hopeless 53. tender
12. bashful 33. impatient 54. tense
13. blue 34. kindly 55. terrible
14. bored 35. lonely 56. timid
15. calm 36. lost 57. tormented
16. cautious 37. low 58. understanding
17. cooperative 38. mad 59. unhappy
18. cruel 39. merry 60. upset
19. daring 40. mild 61. warm
20. devoted 41. miserable 62. wilted
21. disagreeable 42. nervous 63. worrying
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APPENDIX K
MENSTRUAL DISTRESS QUESTIONNAIRE
(Form T)
Name
Today's Date
On the next two pages is a list of symptoms which
women sometimes experience. For each symptom choose
the descriptive category listed below which best
describes your experience of that symptom today .
Circle the number of the category which best describes
your experience of the symptom today . Even if none of
the categories is exactly correct, choose the one that
best describes your experience. Please be sure to
circle one number for each symptom. Please also
remember to put your name and date in the blank spaces
at the top of this page.
Descriptive Categories
1 - no experience of symptom
2 - barely noticeable
3 - present, mild
4 - present, moderate
5 - present, strong
6 - acute or partially disabling
1. 1 2 3 4 5 6
2. 1 2 3 4 5 6
3 . 1 2 3 4 5 6
4. Lowered school or
1 2 3 4 5 6
5. Muscle stiffness 1 2 3 4 5 6
6. 1 2 3 4 5 6
7. Confusion 1 2 3 4 5 6
8. Take naps or
1 2 3 4 5 6
9. 1 2 3 4 5 6
10. Skin Disorders 1 2 3 4 5 6
11. 1 2 3 4 5 6
12. Feelings of Suffocation. 1 2 3 4 5 6
13 . 1 2 3 4 5 6
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14.
15.
Orderliness
Stay home from
1 3J 4 5 6
16.
work or school
Cramps (uterine or
1 2 •J b 6
17.
1 2 •3 5Dizziness or faintness.. 1 2 3 5
6
18.
19.
Excitement
Chest pains
1
1
2
2
3
3 A**
c3
c
6
6
c.
20. Avoid social activities. 1 2 3 4. c
O
21. Anxiety 1 2 3 4. c
D
a
22.
23 .
Backache
Cold sweats
1
1
CM
CM
3
3
TT
4.**
4.**
3
c
c3
O
aD
b24. Lowered judgment 1 2 3 4.** c a
25. Fatigue 1 2 3 4. c
O
cD26. Nausea or vomiting 1 2 3 ZLre c 527. Restlessness 1 2 3 4 •J c.28. Hot flashes 1 2 3 4 5
O
29. Difficulty in o
concentration 1 2 3 4 5
30. Painful or tender
31.
breasts 1 2 3 4 5 g
Feelings of well-being.
.
1 2 3 4 5
32. Buzzing or ringing
1 2 3 4 5
33. Distractable 1 2 3 4 5 6
34. Swelling (e.g., abdomen.
breasts or ankles ) . . . 1 2 3 4 5 6
35. Accidents (e.g., cut
finger, break dish) . . 1 2 3 4 5 6
36. Irritability 1 2 3 4 5 6
37. General aches and pains 1 2 3 4 5 6
38. Mood swings 1 2 3 4 5 6
39. Heart pounding 1 2 3 4 5 6
40. Depression (feeling
1 2 3 4 5 6
41. Decreased efficiency. . . 1 2 3 4 5 6
42. Lowered motor
1 2 3 4 5 6
43. Numbness or tingling
in hands or feet 1 2 3 4 5 6
44. Change in eating habits. 1 2 3 4 5 6
45. 1 2 3 4 5 6
46. Blind spot or
1 2 3 4 5 6
47. Bursts of energy or
1 2 3 4 5 6
Copyright: Rudolf H. Moos, 1968, 1977
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